Patient Reported Outcomes from research to clinical practice. Opportunities and future challenges
DOI:
https://doi.org/10.33393/ao.2023.2575Keywords:
Cancer Clinical Care, Clinical Trial, Patient Empowerment, Patient Engagement, Patient Reported Outcomes, PROsAbstract
PROs, highly considered tools for the personalization of therapies and for research, are still scarcely used in clinical practice. Patient organizations played an important role in the validation process of these tools and are engaged in their dissemination and development.
Downloads
References
Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57(5):278-300. https://doi.org/10.3322/CA.57.5.278 PMID:17855485 DOI: https://doi.org/10.3322/CA.57.5.278
Basch E, Snyder C, McNiff K, et al. Patient-reported outcome performance measures in oncology. J Oncol Pract. 2014;10(3):209-211. https://doi.org/10.1200/JOP.2014.001423PMID:24756142 DOI: https://doi.org/10.1200/JOP.2014.001423
Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244. https://doi.org/10.1093/jnci/dju244 PMID:25265940 DOI: https://doi.org/10.1093/jnci/dju244
Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910-915. https://doi.org/10.1200/JCO.2014.57.9334 PMID:25624439 DOI: https://doi.org/10.1200/JCO.2014.57.9334
Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017;318(2):197-198. https://doi.org/10.1001/jama.2017.7156 PMID:28586821 DOI: https://doi.org/10.1001/jama.2017.7156
2008 Erice Group. The 2008 Erice statement toward a more humanistic oncology. J Ambul Care Manage. 2009 Jul-Sep;32(3):252-8. Erratum in: J Ambul Care Manage. 2016 Oct-Dec;39(4):342. https://doi.org/10.1097/JAC.0b013e3181ac9d81. PMID 19542815. DOI: https://doi.org/10.1097/JAC.0b013e3181ac9d81
Erice Group: "L'Umanizzazione in Oncologia". Il Sole 24 Ore Sanità, 28 Ottobre - 03 Novembre 2008
C. Caminiti, M. Bagnalasta, F. Arpinelli, et al. P14 Cross-cultural adaptation, evaluation and validation of the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE): a study protocol. Ann Oncol 2015;26(S6): vi123–vi131. https://doi.org/10.1093/annonc/mdv347.14 DOI: https://doi.org/10.1093/annonc/mdv347.14
S. Riva, C. Caminiti, E. Iannelli, et al. S08 Cross-cultural adaptation of the US National Cancer Institute's PRO-CTCAE instrument into Italian for adult cancer patients. Ann Oncol 2016;26(S4). https://doi.org/10.1093/annonc/mdw345.08 DOI: https://doi.org/10.1093/annonc/mdw345.08
Caminiti C, Bryce J, Riva S, et al. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). Tumori. 2022 Jun 8:3008916221099558. https://doi.org/10.1177/03008916221099558 PMID 35674125 DOI: https://doi.org/10.1177/03008916221099558
F. Perrone, M. Di Maio, E. Iannelli. La centralità del paziente ed evoluzione dei Patient-Reported Outcomes (PROs) nella sperimentazione e nella pratica clinica. PROFFIT – il nuovo strumento per misurare la tossicità finanziaria in: 12° Rapporto sulla condizione assistenziale dei malati oncologici. Osservatorio FAVO sulla condizione assistenziale dei malati oncologici 2020. Online https://osservatorio.favo.it/wp-content/uploads/2020/10/quaderno_FAVO_2020.pdf (Accessed February 2023)
S. Riva, J. Bryce, F. De Lorenzo, et al. Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. BMJ Open. 2019 Sep 9;9(9):e031485. https://doi.org/10.1136/bmjopen-2019-031485 PMID 31501130 DOI: https://doi.org/10.1136/bmjopen-2019-031485
S Riva, M Di Maio, F Efficace, et al. 1663P Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT). Ann Oncol 2019;30(S5): V681. https://doi.org/10.1093/annonc/mdz263.034 DOI: https://doi.org/10.1093/annonc/mdz263.034
J Bryce, S Riva, M Di Maio, F Efficace, L Frontini, C Gallo, D Giannarelli, V Montesarchio, F De Lorenzo, L Del Campo, E Iannelli, et al. Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT). Journal of Clinical Oncology 2019 37:27_suppl, 91-91. https://doi.org/10.1200/JCO.2019.37.27_suppl.91 DOI: https://doi.org/10.1200/JCO.2019.37.27_suppl.91
Riva S, Arenare L, Di Maio M, et al. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. BMJ Open. 2021;11(10):e049128. https://doi.org/10.1136/bmjopen-2021-049128 PMID:34670762 DOI: https://doi.org/10.1136/bmjopen-2021-049128
Riva S, Efficace F, Di Maio M, et al. A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. Support Care Cancer. 2021;29(6):3219-3233. https://doi.org/10.1007/s00520-020-05840-zPMID:33094357 DOI: https://doi.org/10.1007/s00520-020-05840-z
Di Maio M, Basch E, Denis F, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. https://doi.org/10.1016/j.annonc.2022.04.007 PMID:35462007 DOI: https://doi.org/10.1016/j.annonc.2022.04.007
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Elisabetta Iannelli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.
Accepted 2023-04-03
Published 2023-04-18
